Global Blood Therapeutics, Inc. (NASDAQ:GBT) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -9.69% to close at $17.25 with the total traded volume of 1.64 Million shares. Global Blood Therapeutics reports new long-term clinical data from ongoing Phase 1/2 Trial of GBT440; showed treatment led to reduction in hemolysis and sickled cells in all patients treated for up to 6 months (GBT). The firm announced the presentation of results from its ongoing Phase 1/2 GBT440-001 study that further support the safety and efficacy profile of GBT440 as a potentially disease-modifying therapy for sickle cell disease.
Results presented at ASH showed: All 41 SCD patients receiving GBT440 for up to six months have shown a profound and durable reduction in hemolysis (red blood cell destruction) as assessed by hemoglobin, reticulocytes and/or bilirubin. All patients taking GBT440 showed profound and durable reductions in irreversibly sickled cells compared with those taking placebo. The firm has institutional ownership of 96.20%, while insider ownership included 0.20%. GBT attains analyst recommendation of 1.80 with week performance of -4.43%.
Monsanto Company (NYSE:MON) [Trend Analysis] climbed reacts as active mover, shares a gain 0.35% to traded at $104.27 and the percentage gap between open changing to regular change was 0.27%. U.S. seed firm Monsanto Co. (MON) announced Monday that independent proxy advisory firms Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC have both recommended that Monsanto shareowners vote “FOR” the proposal for the $66 billion acquisition by German conglomerate Bayer AG. Under the terms of the merger agreement, Monsanto shareowners will receive $128 per share in cash at the closing of the merger.
The merger agreement is being submitted to a vote at a special meeting of Monsanto shareowners to be held on December 13.According to ISS, the offer represents a 41.7 percent premium to the unaffected price, and that it does not appear to be opportunistic and no superior proposals have been publicly disclosed, despite a reasonable 3.3 percent termination fee. The firm’s current ratio calculated as 1.20 for the most recent quarter. The firm past twelve months price to sales ratio was 3.37 and price to cash ratio remained 24.48. As far as the returns are concern, the return on equity was recorded as 30.80% and return on investment was 12.40% while its return on asset stayed at 6.60%. The firm has total debt to equity ratio measured as 1.99.